Thrasos Therapeutics
Discovers and develops targeted therapies for the prevention and treatment of severe organ failures.
Launch date
Employees
Market cap
-
Enterprise valuation
€76—115m (Dealroom.co estimates Mar 2015.)
Montreal Quebec (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$35.0m | Series C | ||
$21.0m | Series D | ||
| Total Funding | €50.9m | ||
Related Content
Recent News about Thrasos Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.